1
|
Xia L, Kang D, Wan D, Chu C, Chen M, Zhang S, Li X, He L, Yan J, Liu T, Peng Y. Honokiol-Chlorambucil Co-Prodrugs Selectively Enhance the Killing Effect through STAT3 Binding on Lymphocytic Leukemia Cells In Vitro and In Vivo. ACS OMEGA 2020; 5:19844-19852. [PMID: 32803080 PMCID: PMC7424726 DOI: 10.1021/acsomega.0c02832] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/14/2020] [Accepted: 07/17/2020] [Indexed: 05/08/2023]
Abstract
The broad-spectrum DNA alkylating therapeutic, chlorambucil (CBL), has limited safety and shows lower therapy effect because of a short half-life while used in the clinic. Therefore, it is very necessary to develop a more efficient and safer type of CBL derivate against tumors with selective targeting of cancer cells. In addition, the natural product of honokiol (HN), the novel potent chemo-preventive or therapeutic entity/carrier, can target the mitochondria of cancer cells through STAT3 to prevent cancer from spreading and metastasizing. In this study, we designed and synthesized the honokiol-chlorambucil (HN-CBL) co-prodrugs through carbonate ester linkage conjugating with the targeted delivery help of the HN skeleton in cancer cells. Biological evaluation indicated that HN-CBL can remarkably enhance the antiproliferation of human leukemic cell lines CCRF-CEM, Jurkat, U937, MV4-11, and K562. Furthermore, HN-CBL can also selectively inhibit the lymphocytic leukemia (LL) cell survival compared to those mononuclear cells derived from healthy donors (PBMCs), enhance mitochondrial activity in leukemia cells, and induce LL cell apoptosis. Molecular docking and western blot study showed that HN-CBL can also bind with the STAT3 protein at some hydrophobic residues and downregulate the phosphorylation level of STAT3-like HN. Significantly, HN-CBL could dramatically delay leukemia growth in vivo with no observable physiological toxicity. Thus, HN-CBL may provide a novel and effective targeting therapeutic against LL with fewer side effects.
Collapse
Affiliation(s)
- Li Xia
- School of Traditional
Chinese Medicine, Guangdong Food and Drug
Vocational College, Guangzhou 510520, PR China
| | - Dali Kang
- School of Traditional
Chinese Medicine, Guangdong Food and Drug
Vocational College, Guangzhou 510520, PR China
- Department
of Pediatrics, Xiangya Hospital, Central
South University, Changsha 410008, PR China
| | - Dan Wan
- Institute
of Chinese Medicine, Hunan Academy of Traditional Chinese Medicine&Innovation
Centre for Science and Technology, Hunan
University of Chinese Medicine, Changsha 410208, PR China
- College of Life Science, Molecular Science and Biomedicine
Laboratory, State Key Laboratory for Chemo/Bio-Sensing and Chemometrics, Hunan University, Changsha 410082, PR China
| | - Chu Chu
- College of Pharmaceutical Science, Zhejiang
University of Technology, Hangzhou 310014, PR China
| | - Meizi Chen
- Department
of General Internal Medicine, The First
People’s Hospital of Chenzhou, Chenzhou 423000, PR China
| | - Shuihan Zhang
- Institute
of Chinese Medicine, Hunan Academy of Traditional Chinese Medicine&Innovation
Centre for Science and Technology, Hunan
University of Chinese Medicine, Changsha 410208, PR China
| | - Xiong Li
- Institute
of Chinese Medicine, Hunan Academy of Traditional Chinese Medicine&Innovation
Centre for Science and Technology, Hunan
University of Chinese Medicine, Changsha 410208, PR China
- School of Clinical Pharmacy/The First Hospital, Guangdong Pharmaceutical University, Guangzhou 510006, PR China
| | - Leye He
- Department of Urological Surgery and Research Institute
for Prostate Disease, Third Xiangya Hospital,
Central South University, Changsha 410013, PR China
| | - Jianye Yan
- Institute
of Chinese Medicine, Hunan Academy of Traditional Chinese Medicine&Innovation
Centre for Science and Technology, Hunan
University of Chinese Medicine, Changsha 410208, PR China
| | - Teng Liu
- Department
of Pediatrics, Xiangya Hospital, Central
South University, Changsha 410008, PR China
- . Phone: +86-731- 89753044
| | - Yongbo Peng
- Institute
of Chinese Medicine, Hunan Academy of Traditional Chinese Medicine&Innovation
Centre for Science and Technology, Hunan
University of Chinese Medicine, Changsha 410208, PR China
- College of Life Science, Molecular Science and Biomedicine
Laboratory, State Key Laboratory for Chemo/Bio-Sensing and Chemometrics, Hunan University, Changsha 410082, PR China
- . Phone: +86-731-88821894
| |
Collapse
|